Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC.

ABSTRACT:

Introduction

The introduction of consolidation immunotherapy after chemoradiotherapy has improved outcome for patients with locally advanced non-small cell lung cancer. However, not all patients receive this treatment. This study identifies factors associated with failure to start durvalumab as consolidation therapy with the aim of optimizing treatment, supportive care and prehabilitation to ensure that more patients complete the planned treatment.

Materials and methods

Patients from two clinical trials and a named patient use program, were included in this study. All patients received platinum-doublet chemotherapy concomitant with radiotherapy to a total dose of 60-66 gray. Patient characteristics, cancer treatment, toxicity, performance status and laboratory data before an

SUBMITTER: Langberg CW 

PROVIDER: S-EPMC10354813 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature